Survival Rates Rise for Hodgkin Lymphoma Patients Receiving Stem Cell Transplants
A retrospective study found that outcomes for relapsed or refractory classical Hodgkin lymphoma patients undergoing hematopoietic cell transplantation have significantly improved over time. The registry-based cohort analysis shows better survival and reduced complications in recent years. These findings highlight advances in transplant care for this cancer.
The analysis drew on records from over 600 transplant centers across 53 countries, tracking nearly 20,000 adults treated between 2010 and 2022. The research team separated patients into two groups based on transplant type, with the majority receiving autologous grafts.
Beyond survival gains, the study identified specific clinical factors influencing outcomes. Achieving complete remission before the transplant procedure, along with younger age and better physical function, correlated with improved progression-free survival. For allogeneic recipients, modern approaches like reduced-intensity conditioning and post-transplant cyclophosphamide also contributed to better results.
The findings could reassure patients facing relapsed or refractory Hodgkin lymphoma, as treatment protocols have become more effective over the past decade. Improved survival rates may influence clinical decision-making, potentially encouraging more aggressive use of transplantation or refining patient selection criteria. Healthcare systems could see shifts in resource allocation, as newer supportive therapies and conditioning regimens become standard. Ultimately, these trends suggest that ongoing refinements in transplant care are translating into tangible, long-term benefits for a specific cancer population.